| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Sales Highlights:
| Global | • | FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) |
| • | June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter | |
| Australia | • | FY 2024 AUD$3.7 million up 223% on pcp |
| • | June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter | |
| USA | • | FY 2024 Record sales of AUD$1.1 million up 74% on pcp |
| • | June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior quarter | |
| Canada | • | FY2024 AUD$0.1 million up 6637% on pcp |
MELBOURNE, Australia, July 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.
Flavio Palumbo, Chief Commercial Officer, said, "We continue to be excited by the strong sales results on Travelan®. Immuron's investment to drive awareness of the Travelan® brand has seen continued strong sales results in Australia. We were incredibly pleased to achieve record U.S. sales in FY24. We hope to achieve strong North American growth in FY25 on the back of planned increased brand investment and distribution."
Australia
Sales of Travelan® increased 236% to AUD $3.7 million for the full financial year to June 2024 (FY24) compared to AUD $1.1 million for FY23. Sales of Travelan® increased 209% to AUD $1.0 million for the June 2024 Quarter compared to AUD $0.3 million for the June 2023 Quarter (excludes sales of Protectyn®).
Consistent with the increase in June 2024 quarter sales, the Australian Bureau of Statistics reported short term resident returns in April 2024 were 29% higher than April 20231.
USA
We achieved a new annual record. The previous highest annual USA sales was AUD $1.0 million in FY19.
Sales of Travelan® increased 74% to AUD $1.1 million for the full financial year to June 2024 (FY24) compared to AUD $0.6 million for FY23.
Sales of Travelan® increased 546% to AUD $0.3 million in the June 2024 Quarter compared to AUD $0.05 million in the June 2023 Quarter.
Immuron's experience in the USA follows the International Trade Administration Total U.S. citizen international visitor departures from the United States in April 2024 being 8% higher than in April 2023.2
Posted In: IMRN
